Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis

Phase 4RecruitingNCT07045155

Chinese PLA General Hospital240 enrolled

Overview

This study is a prospective, multicenter, parallel-controlled, open-label clinical trial, planned to be conducted across multiple research centers in various provinces and cities in China. It will enroll 240 dialysis-dependent chronic kidney disease (DD-CKD) patients with anemia who have been receiving rHuEPO treatment for at least 4 weeks, with hemoglobin (Hb) levels of ≥70 g/L and \<110 g/L. After enrollment, participants will be randomly assigned in a 1:1:1 ratio to the experimental group, control group, and exploratory group. The study will involve a 24-week treatment and observation period, divided into three phases: a screening period (Day -28 to Day -1), a treatment period (Week 0 to Week 16), and an extension period (Week 17 to Week 24). The primary objective is to assess the impact of the three treatment regimens on the hemoglobin levels of patients with DD-CKD anemia.

title： Pegmolesatide for anemia treatment：investigation upgrade therapy in rhuEPO patients undergoing dialysis: A Prospective, Multicenter, Parallel-Group, Controlled, Open-Label Study（PANGU-upgrade） Introduction: Anemia is a primary complication of chronic kidney disease (CKD). In recent years, there have been many effective strategies for treating anemia in CKD, including erythropoiesis-stimulating agents (ESAs), hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), and erythropoietin (EPO) mimetic peptides (EMPs) such as Pegmolesatide. This study aims to explore the efficacy and safety of switching patients with anemia of dialysis-dependent chronic kidney disease (DD-CKD), whose hemoglobin (Hb) levels have not reached the target after treatment with recombinant human erythropoietin (rHuEPO), to treatment with pegmolesatide. Methods: This study is designed as a prospective, multicenter, parallel-controlled, open-label trial. It plans to enroll 240 participants with anemia of dialysis-dependent chronic kidney disease (DD-CKD) who have been receiving recombinant human erythropoietin (rHuEPO) treatment for at least 4 weeks, with hemoglobin (Hb) levels of ≥70 g/L and \<110 g/L. Participants will be randomly assigned in a 1:1:1 ratio to the experimental group, the control group, and the exploratory group. The study will consist of a 24-week treatment and observation period, divided into three phases: the screening period (Day -28 to Day -1), the treatment period (Week 0 to Week 16), and the extension period (Week 17 to Week 24). This study plans to recruit participants from 20 large tertiary hospitals across multiple provinces and cities in China. The primary endpoint of the study is the change in mean hemoglobin (Hb) levels from baseline at weeks 12 to 16 of treatment in the three groups. The study will observe and evaluate the efficacy and safety of switching patients with anemia of dialysis-dependent chronic kidney disease (DD-CKD) who have not achieved target Hb levels after treatment with recombinant human erythropoietin (rHuEPO) to treatment with pegmolesatide alone or pegmolesatide in combination with roxadustat.

Interventions

The rHuEPO Monotherapy Group (Control Group)DRUG

The rHuEPO Monotherapy Group (Control Group) will be treated with rHuEPO for the first 16 weeks and then switch to Pegmolesatide treatment for the subsequent 8 weeks.

The Pegmolesatide and Roxadustat Combination Therapy Group (Exploratory Group)DRUG

The Pegmolesatide and Roxadustat Combination Therapy Group (Exploratory Group) will receive a combination of Pegmolesatide and roxadustat throughout the entire 24-week treatment period.

The Pegmolesatide Monotherapy Group (Experimental group)DRUG

The Pegmolesatide Monotherapy Group (Experimental Group) will receive Pegmolesatide treatment throughout the entire 24-week period.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Aged ≥18 years and ≤80 years, with no restrictions on gender. 2. Body weight ≥40 kg and body mass index (BMI) ≥18 kg/m². 3. Subjects who have received hemodialysis or peritoneal dialysis for ≥3 months prior to enrollment; 4. Subjects who have been receiving erythropoiesis-stimulating agents (ESAs) for ≥4 weeks prior to randomization, with an average weekly dose \>6000 IU in the last 4 weeks (equivalent dose converted to short-acting EPO \>6000 IU, calculated as the total amount of short-acting EPO used in the last 4 weeks divided by 4); 5. The most recent Hb value during the screening period and the average Hb value between screening and baseline visits must be ≥70 to \<110 g/L; 6. Hemodialysis patients with serum ferritin levels ≥200 μg/L; peritoneal dialysis patients with serum ferritin levels ≥100 μg/L, and the investigator determines that renal transplant is not required during the trial; 7. Understanding the study procedures and voluntarily signing the Informed Consent Form (ICF). Exclusion Criteria: 1. Known to have active malignancy, polycystic kidney disease, hematologic disorders (including congenital and acquired anemias such as thalassemia, Fanconi anemia, pure red cell aplasia, myelodysplastic syndromes, hemolytic anemia, and coagulation disorders), or other causes of anemia (such as gastrointestinal bleeding or hookworm disease); 2. Known to have experienced stroke, transient ischemic attack, myocardial infarction, thromboembolic events (deep vein thrombosis), pulmonary embolism, or other serious cardiopulmonary diseases within the past 6 months; 3. Received anabolic steroid (e.g., androgen) therapy within 12 weeks prior to randomization; 4. Known to have received red blood cell or whole blood transfusion within 12 weeks prior to the study. 5. History of significant infection within 4 weeks before randomization as determined by the investigator. 6. Confirmed blood pressure measurements at rest and in a conscious state using standard measurement methods, with at least three non-consecutive day readings reaching or exceeding systolic blood pressure (SBP) ≥180 mmHg and/or diastolic blood pressure (DBP) ≥110 mmHg within 4 weeks before enrollment, or changes in antihypertensive medication treatment. The primary basis for judgment is clinic-measured blood pressure values, but "white coat hypertension" should be excluded. 7. Known allergy to iron agents or polyethylene glycol. 8. Pregnant or breastfeeding women, women of childbearing age with a positive blood β-HCG test result before the trial, or those planning to become pregnant during the study period. 9. Scheduled for elective surgery during the trial period. 10. Presence of any other factors that the investigator deems unsuitable for participation in this trial.

Outcomes

Primary Outcomes

The change in mean hemoglobin (Hb) levels from baseline at weeks 12 to 16 of treatment in the three groups.

Primary efficacy endpoints

Time frame: During weeks 12 to 16 of the study treatment

Secondary Outcomes

The proportion of participants in the three groups with mean Hb levels ≥100 g/L and ≤120 g/L at weeks 12 to 16 and weeks 20 to 24 of treatment.

secondary efficacy endpoints

Time frame: During weeks 12 to 16 and weeks 20 to 24 of the study treatment

The proportion of participants in the three groups with mean Hb levels ≥110 g/L and ≤130 g/L at weeks 12 to 16 and weeks 20 to 24 of treatment.

secondary efficacy endpoints

Time frame: During weeks 12 to 16 and weeks 20 to 24 of the study treatment

The proportion of participants in the three groups with mean Hb levels ≥100 g/L at weeks 12 to 16 and weeks 20 to 24 of treatment.

secondary efficacy endpoints

Time frame: During weeks 12 to 16 and weeks 20 to 24 of the study treatment

The proportion of participants in the three groups with mean Hb levels ≥110 g/L at weeks 12 and 24 of treatment.

secondary efficacy endpoints

Time frame: at weeks 12 and 24 of treatment.

The median time to first reach the target Hb level (110-130 g/L) during the treatment period in the three groups.

secondary efficacy endpoints

Time frame: up to 24 weeks

The absolute values of hemoglobin (Hb) levels during the treatment period in the three groups.

secondary efficacy endpoints

Time frame: up to 24 weeks

The absolute values of changes in hemoglobin (Hb) levels from baseline during the treatment period in the three groups.

secondary efficacy endpoints

Time frame: up to 24 weeks

The absolute values of red blood cell (RBC) count levels during the treatment period in the three groups.

secondary efficacy endpoints

Time frame: up to 24 weeks

The absolute values of hematocrit levels during the treatment period in the three groups.

secondary efficacy endpoints

Time frame: up to 24 weeks

The dosage of the study drug used between each pair of consecutive follow-up visits during the treatment period in the three groups.

secondary efficacy endpoints

Time frame: up to 24 weeks

The average dosage of the study drug used by participants with Hb levels within the target range (100 g/L ≤ Hb ≤ 120 g/L) at each follow-up visit during the treatment period in the three groups.

secondary efficacy endpoints

Time frame: up to 24 weeks

The average dosage of the study drug used by participants with Hb levels within the target range (110 g/L ≤ Hb ≤ 130 g/L) at each follow-up visit during the treatment period in the three groups.

secondary efficacy endpoints

Time frame: up to 24 weeks

The total number of dosage adjustments at weeks 12 and 24 in the three groups.

secondary efficacy endpoints

Time frame: At weeks 12 and 16 of the study treatment

The rate of Hb increase during the first 4 weeks and first 8 weeks of treatment in the three groups.

secondary efficacy endpoints

Time frame: during the first 4 weeks and first 8 weeks of treatment in the three groups.

The proportion of participants receiving rescue therapy during the treatment period in the three groups.

secondary efficacy endpoints

Time frame: up to 24 weeks

Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts